Decision Resources, Inc., announces the publication of Allergic Rhinitis, a new study that assesses promising therapies and their projected impact on the allergic rhinitis (AR) market over a 1999-2009 forecast period. AR affects nearly 150 million people in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Furthermore, allergy experts estimate that only 30-45% of AR patients are actually diagnosed with the condition. Consequently, there is a vast population of AR sufferers who could benefit from prescription medications that are either more potent or produce fewer side effects than available over-the-counter (OTC) drugs.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION)

Two of the most advanced agents in clinical trials for AR received approval in Europe in January 2001: Schering-Plough's desloratadine and UCB's levocetirizine. These third-generation antihistamines will vie for market share in Europe in the coming years. Desloratadine was also recommended for approval in the United States in early 2000, but final approval of the drug has been delayed due to manufacturing issues-- the US FDA and Schering-Plough are currently working to resolve these issues. Sepracor's norastemizole is another third-generation antihistamine that is expected to enter the US market in 2002. Marketers of these "next-generation" antihistamines will position their new drugs as improved versions of their popular predecessors--loratadine [Schering-Plough's Claritin], cetirizine [UCB's Zyrtec], and astemizole [Janssen's Hismanal].

Sales of prescription drugs to treat AR in the seven major pharmaceutical markets are expected to surpass $5.6 billion by 2009. The chief factors fueling this growth will be increases in the diagnosed population across all markets as the public becomes more aware of prescription drug treatments, and the introduction of more potent-and expensive-therapies.

Allergic Rhinitis is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or sama@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail).

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, 781-296-2553,
sama@dresources.com

Decision Resources Report Evaluates Emerging Cancer Drug Delivery Technologies

View Now